The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)

Severe Romiplostim-Induced Rebound Thrombocytopenia After Splenectomy for Refractory ITP

(2014) Michael J. Choe et al.   ANNALS OF PHARMACOTHERAPY

The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study

(2014) Matthieu Mahévas et al.   BRITISH JOURNAL OF HAEMATOLOGY

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

(2013) G. D'Arena et al.   BLOOD

Individualized Treatment for Immune Thrombocytopenia: Predicting Bleeding Risk

(2013) Cindy E. Neunert   SEMINARS IN HEMATOLOGY

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms

(2012) Nicola Polverelli et al.   BRITISH JOURNAL OF HAEMATOLOGY

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents

(2010) W. Bao et al.   BLOOD

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

(2008) David J Kuter et al.   LANCET